Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the June 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Treatment FDA Approves Darolutamide For mHSPC The FDA has approved darolutamide (Nubeqa) for metastatic hormone-sensitive prostate cancer (mHSPC) based on results from the ARANOTE trial. Darolutamide significantly improved radiographic progression-free survival. » Full Article from the FDA Side Effects How Does Androgen Receptor Inhibition Affect Quality of Life? ZERO Medical Advisory Board chair Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses more detailed information about quality of life measures from the ARANOTE trial. » Full Video from ASCO Post Outcomes AMPLITUDE: First Trial to Demonstrate Improved rPFS in HRR-Altered mCSPC With Combination PARP Inhibitor + Standard of Care The AMPLITUDE trial is the first to show that combining a PARP inhibitor (niraparib) with abiraterone plus prednisone improves radiographic progression-free survival in men with mHSPC and homologous recombination repair (HRR) gene mutations. » Full Article from ASCO Daily News Diagnostics Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men A cross-comparison study of over 50,000 patients found only minimal to moderate correlation between the Decipher genomic classifier and other commercial tests like Prolaris. » Full Article from ASCO Publications Outcomes Radiotherapy for Prostate Cancer: 2- vs 8-Week Course Ten-year results from the HYPO-RT-PC phase 3 trial confirm that the 2.5-week ultra-hypofractionated radiotherapy is as safe and effective as the traditional 8-week regimen for localized prostate cancer. » Full Article from ASCO Post Health Equity Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials A large study evaluated whether an artificial intelligence (AI) model predicting distant metastasis and prostate cancer-specific mortality performed equally across racial groups. » Full Article from ASCO Publications Outcomes Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC Results from the COMRADE trial showed that combining olaparib (Lynparza) with radium-223 (Ra223) significantly improved radiographic progression-free survival in patients with mCRPC and bone metastases. » Full Article from Cancer Network Outcomes CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer In a phase 3 trial, adding CAN-2409, a gene therapy activating a cytolytic immune response, to external beam radiation significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer. » Full Article from Cancer Network Treatment Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in mCRPC: A Phase I Study A phase 1 trial of Pasritamig, a first-in-class bispecific antibody targeting kallikrein 2 (KLK2) on prostate cancer cells, showed a favorable safety profile and early signs of antitumor activity in patients with mCRPC. » Full Article from ASCO Publications ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the June 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Treatment FDA Approves Darolutamide For mHSPC The FDA has approved darolutamide (Nubeqa) for metastatic hormone-sensitive prostate cancer (mHSPC) based on results from the ARANOTE trial. Darolutamide significantly improved radiographic progression-free survival. » Full Article from the FDA Side Effects How Does Androgen Receptor Inhibition Affect Quality of Life? ZERO Medical Advisory Board chair Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses more detailed information about quality of life measures from the ARANOTE trial. » Full Video from ASCO Post Outcomes AMPLITUDE: First Trial to Demonstrate Improved rPFS in HRR-Altered mCSPC With Combination PARP Inhibitor + Standard of Care The AMPLITUDE trial is the first to show that combining a PARP inhibitor (niraparib) with abiraterone plus prednisone improves radiographic progression-free survival in men with mHSPC and homologous recombination repair (HRR) gene mutations. » Full Article from ASCO Daily News Diagnostics Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 Men A cross-comparison study of over 50,000 patients found only minimal to moderate correlation between the Decipher genomic classifier and other commercial tests like Prolaris. » Full Article from ASCO Publications Outcomes Radiotherapy for Prostate Cancer: 2- vs 8-Week Course Ten-year results from the HYPO-RT-PC phase 3 trial confirm that the 2.5-week ultra-hypofractionated radiotherapy is as safe and effective as the traditional 8-week regimen for localized prostate cancer. » Full Article from ASCO Post Health Equity Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials A large study evaluated whether an artificial intelligence (AI) model predicting distant metastasis and prostate cancer-specific mortality performed equally across racial groups. » Full Article from ASCO Publications Outcomes Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC Results from the COMRADE trial showed that combining olaparib (Lynparza) with radium-223 (Ra223) significantly improved radiographic progression-free survival in patients with mCRPC and bone metastases. » Full Article from Cancer Network Outcomes CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer In a phase 3 trial, adding CAN-2409, a gene therapy activating a cytolytic immune response, to external beam radiation significantly improved disease-free survival in patients with intermediate-to-high-risk localized prostate cancer. » Full Article from Cancer Network Treatment Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in mCRPC: A Phase I Study A phase 1 trial of Pasritamig, a first-in-class bispecific antibody targeting kallikrein 2 (KLK2) on prostate cancer cells, showed a favorable safety profile and early signs of antitumor activity in patients with mCRPC. » Full Article from ASCO Publications ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
